Clinical Trial Update: A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and potential efficacy of LT3001 in subjects with acute ischemic stroke; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• LT3001

Snippet

Sponsor: Lumosa Therapeutics Co., Ltd. | Conditions: Acute Ischemic Stroke | Phase 2 | Status: COMPLETED | Results posted: 2025-12-30